In another study, the combination of SFN and Withaferin A blocked cell cycle progression from the S to G2 phase in breast cancer cell lines by down-regulating cyclin D1, cyclin dependent kinase 4 (CDK4), and pRB with a concomitant increase in p21 and E2F mRNA levels. The gene discussed is CDKN1A; the disease is breast carcinoma.